Baert L
Curr Med Res Opin. 1974;2(10):631-5. doi: 10.1185/03007997409111875.
A double-blind, placebo-controlled trial of the antispasmodic flavoxate (600 mg. daily) was carried out in 60 patients suffering from painful conditions of the lower urinary tract arising from inflammation and/or infection or from spasm following diagnostic or therapeutic procedures. Statistically significant improvement was noted in frequency and suprapubic pain, and marked relief was also afforded in dysuria, hesitancy and burning. Apart from dryness of the mouth, the incidence and type of side-effects reported were similar in both groups of patients and were probably not drug related. Fewer patients interrupted treatment with flavoxate because of inefficacy than in the placebo group, the difference being statistically significant.
对60例患有因炎症和/或感染引起的下尿路疼痛病症，或因诊断或治疗程序后痉挛引起的下尿路疼痛病症的患者，进行了一项双盲、安慰剂对照试验，试验药物为解痉药黄酮哌酯（每日600毫克）。在尿频和耻骨上区疼痛方面观察到有统计学意义的改善，尿痛、排尿犹豫和烧灼感也有明显缓解。除口干外，两组患者报告的副作用发生率和类型相似，可能与药物无关。因无效而中断黄酮哌酯治疗的患者比安慰剂组少，差异有统计学意义。
